Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

What is the purpose of this trial?

This trial is testing a monoclonal antibody called Avelumab combined with radiation therapy. Researchers are studying whether this combination is safe for treating myeloma and how well it works.

This trial is currently open and accepting patients.


Treatments included in this clinical trial:

  • Avelumab is a monoclonal antibody that targets the programmed death-lignad 1 (PDL1) protein.
  • Radiation is used to fight may types of cancer including multiple myeloma. Cancer cells multiply faster than normal cells in the body. Radiation is most harmful to quickly growing cells, so radiation therapy damanges cancer cells more than normal cells. This stops cancer cells from growing and dividing and leads to cell death.

What will happen during the trial?

  • This trial is open label, which means that both you and the researchers running the study will know the doses of Avelumab and radiation you will be receiving.
  • This study is organized into 28 day cycles, and all patients who join will receive the same regimen.
  • Patients will receive Avelumab through an intravenous infusion every two weeks (on cycle days 1 and 15).
  • After two doses of Avelumab (one cycle), patients will then receive five radiation therapy treatments on consecutive days.
  • Patients may then continue to receive Avelumab every two weeks indefinitely, as long as they don’t develop bad side effects and their myeloma doesn’t get worse.

Additional Trial Information

Phase 2

Enrollment: 30 patients (estimated)

View More
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

  • Have relapsed or refractory multiple myeloma
  • Have at least one plasmacytoma or lytic lesion that would be appropriate to treat with radiation therapy.
View Additional Criteria

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Maryland

National Institutes of Health (NIH)

Bethesda, MD

Accepting